Development of a gene therapy virus with a glucocorticoid-inducible MMP1 for the treatment of steroid glaucoma

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 6, 2010, Pages 3029-3040

  Spiga, Maria Grazia ^a   Borrás, Teresa ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; COLLAGEN TYPE 1; DEXAMETHASONE; GLUCOCORTICOID; INTERSTITIAL COLLAGENASE; PREDNISOLONE ACETATE; TRIAMCINOLONE ACETATE; COLLAGEN; DRUG DERIVATIVE; MESSENGER RNA; MMP1 PROTEIN, HUMAN; PREDNISOLONE; TRIAMCINOLONE ACETONIDE;

AGED; ANTIBODY LABELING; ARTICLE; COLLAGEN DEGRADATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME RELEASE; GENE INDUCTION; GLAUCOMA; HORMONE RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEROID GLAUCOMA; VIRAL GENE DELIVERY SYSTEM; ADENOVIRUS; ADOLESCENT; ADULT; CELL CULTURE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; FEMALE; FLUORESCENCE MICROSCOPY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENE THERAPY; GENE VECTOR; GENETICS; INTRAOCULAR PRESSURE; MALE; METABOLISM; MIDDLE AGED; OPEN ANGLE GLAUCOMA; ORGAN CULTURE TECHNIQUE; PHYSIOLOGY; PRESCHOOL CHILD; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRABECULAR MESHWORK; VIROLOGY; WESTERN BLOTTING;

ADENOVIRIDAE; ADOLESCENT; AGED; BLOTTING, WESTERN; CELLS, CULTURED; CHILD, PRESCHOOL; COLLAGEN; DEXAMETHASONE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE THERAPY; GENETIC VECTORS; GLAUCOMA, OPEN-ANGLE; GLUCOCORTICOIDS; HUMANS; INTRAOCULAR PRESSURE; MALE; MATRIX METALLOPROTEINASE 1; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; ORGAN CULTURE TECHNIQUES; PREDNISOLONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRABECULAR MESHWORK; TRIAMCINOLONE ACETONIDE; YOUNG ADULT;

EID: 77953243082     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4918     Document Type: Article

References (55)

1. Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics, I: the effect of dexamethasone in the normal eye. Arch Ophthalmol. 1963;70: 482-491.
2. Armaly MF, Becker B. Intraocular pressure response to topical corticosteroids. Fed Proc. 1965;24: 1274-1278.
3. Tripathi RC, Parapuram SK, Tripathi BJ, Zhong Y, Chalam KV. Corticosteroids and glaucoma risk. Drugs Aging. 1999;15:439-450.
4. Becker B, Mills DW. Corticosteroids and intraocular pressure. Arch Ophthalmol. 1963;70: 500-507.
5. Kitazawa Y, Horie T. The prognosis of corticosteroid-responsive individuals. Arch Ophthalmol. 1981;99:819-823.
6. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol. 1996;80:389-393.
7. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713.
8. Grant WM. Clinical measurements of aqueous outflow. AMA Arch Ophthalmol. 1951;46:113-131.
9. Wordinger RJ, Clark AF. Effects of glucocorticoids on the trabecular meshwork: towards a better understanding of glaucoma. Prog Retin Eye Res. 1999;18:629-667.
10. Clark AF, Wordinger RJ. The role of steroids in outflow resistance. Exp Eye Res. 2009;88:752-759.
11. Rozsa FW, Reed DM, Scott KM, et al. Gene expression profile of human trabecular meshwork cells in response to long-term dexamethasone exposure. Mol Vis. 2006;12:125-141.
12. Borrás T. What is functional genomics teaching us about intraocular pressure regulation and glaucoma. In: Civan MM, ed. The Eye's Aqueous Humor. 2nd ed. San Diego: Elsevier; 2008:323-377.
13. Johnson D, Gottanka J, Flugel C, Hoffmann F, Futa R, Lütjen- Drecoll E. Ultrastructural changes in the trabecular meshwork of human eyes treated with corticosteroids. Arch Ophthalmol. 1997; 115:375-383.
14. Clark AF, Brotchie D, Read AT, et al. Dexamethasone alters F-action architecture and promotes cross-linked action network formation in human trabecular meshwork tissue. Cell Motil Cytoskeleton. 2005; 60:83-95.
15. Zhang X, Ognibene CM, Clark AF, Yorio T. Dexamethasone inhibition of trabecular meshwork cell phagocytosis and its modulation by glucocorticoid receptor beta. Exp Eye Res. 2007;84:275-284.
16. Steely HT, Browder SL, Julian MB, Miggans ST, Wilson KL, Clark AF. The effects of dexamethasone on fibronectin expression in cultured human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 1992;33:2242-2250.
17. Polansky JR, Fauss DJ, Chen P, et al. Cellular pharmacology and molecular biology of the trabecular meshwork inducible glucocorticoid response gene product. Ophthalmologica. 1997;211:126-139.
18. Aranda A, Pascual A. Nuclear hormone receptors and gene expression. Physiol Rev. 2001;81:1269-1304.
19. Zhang X, Clark AF, Yorio T. Regulation of glucocorticoid responsiveness in glaucomatous trabecular meshwork cells by glucocorticoid receptor-beta. Invest Ophthalmol Vis Sci. 2005;46:4607-4616.
20. Borrás T, Rowlette LL, Erzurum SC, Epstein DL. Adenoviral reporter gene transfer to the human trabecular meshwork does not alter aqueous humor outflow: relevance for potential gene therapy of glaucoma. Gene Ther. 1999;6:515-524.
21. Borrás T, Gabelt BT, Klintworth GK, Peterson JC, Kaufman PL. Non-invasive observation of repeated adenoviral GFP gene delivery to the anterior segment of the monkey eye in vivo. J Gene Med. 2001;3:437-449.
22. Challa P, Luna C, Liton PB, et al. Lentiviral mediated gene delivery to the anterior chamber of rodent eyes. Mol Vis. 2005;11:425-430.
23. Wang WH, McNatt LG, Pang IH, et al. Increased expression of the WNT antagonist sFRP-1 in glaucoma elevates intraocular pressure. J Clin Invest. 2008;118:1056-1064.
24. Poeschla EM, Wong-Staal F. Gene therapy and HIV disease. AIDS Clin Rev. 1995;1-45.
25. Buie LK, Rasmussen CA, Porterfield EC, et al. Self-complementary AAV virus (scAAV) safe and long-term gene transfer in the trabecular meshwork of living rats and monkeys. Invest Ophthalmol Vis Sci. 2010;51:236-248.
26. Keller KE, Aga M, Bradley JM, Kelley MJ, Acott TS. Extracellular matrix turnover and outflow resistance. Exp Eye Res. 2009;88: 676-682.
27. Bradley JM, Vranka J, Colvis CM, et al. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. Invest Ophthalmol Vis Sci. 1998;39:2649-2658.
28. Zhou L, Li Y, Yue BY. Glucocorticoid effects on extracellular matrix proteins and integrins in bovine trabecular meshwork cells in relation to glaucoma. Int J Mol Med. 1998;1:339-346.
29. Shinzato M, Yamashiro Y, Miyara N, et al. Proteomic analysis of the trabecular meshwork of rats in a steroid-induced ocular hypertension model: downregulation of type I collagen C-propeptides. Ophthalmic Res. 2007;39:330-337.
30. Gaton DD, Sagara T, Lindsey JD, Gabelt BT, Kaufman PL, Weinreb RN. Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F(2 alpha)- isopropyl ester treatment. Arch Ophthalmol. 2001;119:1165-1170.
31. Borrás T, Bryant PA, Chisolm SS. First look at the effect of over expression of TIGR/MYOC on the transcriptome of the human trabecular meshwork. Exp Eye Res. 2006;82:1002-1010.
32. Yuan W, Varga J. Transforming growth factor-beta repression of matrix metalloproteinase-1 in dermal fibroblasts involves Smad3. J Biol Chem. 2001;276:38502-38510.
33. Iimuro Y, Nishio T, Morimoto T, et al. Delivery of matrix metalloproteinase- 1 attenuates established liver fibrosis in the rat. Gastroenterology. 2003;124:445-458.
34. Hinz B, Rosch S, Ramer R, Tamm ER, Brune K. Latanoprost induces matrix metalloproteinase-1 expression in human nonpigmented ciliary epithelial cells through a cyclooxygenase-2-dependent mechanism. FASEB J. 2005;19:1929-1931.
35. Aihara M, Lindsey JD, Weinreb RN. Ocular hypertension in mice with a targeted type I collagen mutation. Invest Ophthalmol Vis Sci. 2003;44:1581-1585.
36. Gerometta R, Spiga MG, Borrás T, Candia OA. Treatment of sheep steroid-induced ocular hypertension with a glucocorticoid-inducible MMP1 gene therapy virus. Invest Ophthalmol Vis Sci. 2010; 51:3042-3048.
37. Vittitow JL, Garg R, Rowlette LL, Epstein DL, O'Brien ET, Borrás T. Gene transfer of dominant-negative RhoA increases outflow facility in perfused human anterior segment cultures. Mol Vis. 2002;8:32-44.
38. Fan BJ, Wang DY, Tham CC, Lam DS, Pang CP. Gene expression profiles of human trabecular meshwork cells induced by triamcinolone and dexamethasone. Invest Ophthalmol Vis Sci. 2008;49: 1886-1897.
39. Sellers A, Cartwright E, Murphy G, Reynolds JJ. Evidence that latent collagenases are enzyme-inhibitor complexes. Biochem J. 1977;163:303-307.
40. Chung L, Dinakarpandian D, Yoshida N, et al. Collagenase unwinds triple-helical collagen prior to peptide bond hydrolysis. EMBO J. 2004;23:3020-3030.
41. Johnson DH, Tschumper RC. Human trabecular meshwork organ culture: a new method. Invest Ophthalmol Vis Sci. 1987;28:945-953.
42. Samples JR, Alexander JP, Acott TS. Regulation of the levels of human trabecular matrix metalloproteinases and inhibitor by interleukin- 1 and dexamethasone. Invest Ophthalmol Vis Sci. 1993; 34:3386-3395.
43. Snyder RW, Stamer WD, Kramer TR, Seftor RE. Corticosteroid treatment and trabecular meshwork proteases in cell and organ culture supernatants. Exp Eye Res. 1993;57:461-468.
44. Nordeen SK, Suh BJ, Kuhnel B, Hutchison CA. Structural determinants of a glucocorticoid receptor recognition element. Mol Endocrinol. 1990;4:1866-1873.
45. Enriquez-Harris P, Levitt N, Briggs D, Proudfoot NJ. A pause site for RNA polymerase II is associated with termination of transcription. EMBO J. 1991;10:1833-1842.
46. Windsor LJ, Bodden MK, Birkedal-Hansen B, Engler JA, Birkedal-Hansen H. Mutational analysis of residues in and around the active site of human fibroblast-type collagenase. J Biol Chem. 1994;269: 26201-26207.
47. Limb GA, Matter K, Murphy G, et al. Matrix metalloproteinase-1 associates with intracellular organelles and confers resistance to lamin A/C degradation during apoptosis. Am J Pathol. 2005;166: 1555-1563.
48. Jones R III, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol. 2006;17:163-167.
49. Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology. 2005;112:593-598.
50. Rivera VM, Gao GP, Grant RL, et al. Long-term pharmacologically regulated expression of erythropoietin in primates following AAVmediated gene transfer. Blood. 2005;105:1424-1430.
51. Weichselbaum RR, Kufe D. Translation of the radio- and chemoinducible TNFerade vector to the treatment of human cancers. Cancer Gene Ther. 2009;16:609-619.
52. Fogar P, Navaglia F, Basso D, et al. Heat-induced transcription of diphtheria toxin A or its variants, CRM176 and CRM197: implications for pancreatic cancer gene therapy. Cancer Gene Ther. 2010;17:58-68.
53. Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2007-an update. J Gene Med. 2007;9:833-842.
54. Vandendriessche T. Gene therapy delivers. Hum Gene Ther. 2009; 20:1222-1223.
55. Hauswirth WW, Aleman TS, Kaushal S, et al. Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther. 2008;19:979-990